Sale of BioReference brings $722 million in cash as the company narrows its focus to biotech.
OPK Opko Health Inc.
XNAS 1.77 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
OPK
$1.77
—
What changed
Recent filings, trades and movesKey stats
$1.77
- 52-Week Range
- $0.98 – $1.86
- YTD
- +39.47%
- Straddle Price
- $0.53
- P/C Vol Ratio
- 0.76
- Market Cap
- $1.3B
- Open
- $1.74
- Day Range
- $1.71 – $1.79
- Volume
- 1,736,205
- Prev Close
- $1.73
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 0.95 |
| Cost of Equity (CAPM) | 9.63% (VRP-adj) |
| WACC | 8.72% |
| Volatility Risk Premium | +106.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -13.3% |
| Book / Price | 86.4% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 46.2% |
| FCF Margin (TTM) | -27.0% |
| Debt / Equity | 0.41 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $1.59 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.61 |
| Bollinger Width / SMA20 | 30.1% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $1B |
Peers used for multiples: CI, CNC, ELV, LH, SGRY, UNH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
68%
20-Day Fair Value
≈ by Dec 8, 2026
$1.76
α -0.8%
rank 35%
conviction
54%
40-Day Fair Value
≈ by Jan 6, 2027
$1.76
α -0.8%
rank 35%
conviction
29%
60-Day Fair Value
≈ by Feb 4, 2027
$1.72
α -3.0%
rank 35%
conviction
68%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 25.1× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 11.2× · 6 peers |
| Peer P/B | $2.96 | 17% | median 2.0× · 6 peers |
| Peer P/S | $0.42 | 17% | median 0.6× · 6 peers |
| Market Anchor (SMA50) | $1.59 | 67% | stability 79% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.3B
- Employees
- 2,275
- List Date
- 1995-11-02
- CIK
- 0000944809
- Last Earnings
- Nov 4 after close · −1.1% vs ±32.5% expected
- Headquarters
- Miami, FL
- Homepage
- https://www.opko.com
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 28.81% | -36.51% | 5.74% | -35.03% | 4.83% | -0.79% | -5.49% |
| Feb | -24.87% | 2.29% | -17.39% | -0.99% | 16.00% | -6.25% | -5.20% |
| Mar | -8.72% | 11.33% | 24.79% | 20.86% | -5.14% | -8.06% | 5.84% |
| Apr | -6.39% | -23.08% | -4.55% | -6.87% | -16.87% | -0.44% | -9.70% |
| May | -6.60% | 7.14% | -7.95% | 7.87% | 0.74% | 32.73% | 5.66% |
| Jun | 12.19% | -15.38% | 55.00% | -11.97% | -4.35% | 7.14% | 7.10% |
| Jul | -18.87% | -10.27% | -12.68% | 15.45% | -3.76% | -13.44% | -7.26% |
| Aug | 8.73% | -9.92% | 0.55% | 22.18% | 15.97% | 12.21% | 8.29% |
| Sep | -5.19% | -14.09% | -11.60% | -8.02% | 13.97% | 5.92% | -3.17% |
| Oct | 5.87% | -0.52% | -18.30% | 1.34% | -12.26% | 5.73% | -3.02% |
| Nov | 2.34% | -21.05% | 16.80% | 1.99% | -2.86% | 2.91%* | 0.02% |
| Dec | 24.61% | -14.38% | -1.31% | -3.92% | -4.55% | -- | 0.09% |
| Total | -2.16% | -76.46% | 8.51% | -11.42% | -4.38% | 35.53% | -8.40% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.63
SMA 50: $1.59
SMA 200: $1.36
Current: $1.77
EMA 12: $1.70
EMA 26: $1.64
MACD: 0.0581 | Signal: 0.0150
BULLISH
ADX (14): 35.01
TREND
+DI: 27.36
−DI: 13.11
Momentum Oscillators
RSI (14): 65.02
NEUTRAL
Stoch %K: 65.52
Stoch %D: 71.52
Williams %R: -30.36
Volume & Volatility
BB Upper: $1.86
BB Lower: $1.40
NEUTRAL
OBV: 111,127,191
Vol SMA 20: 6,486,342
Vol ROC: -9.47%
ATR: $0.09
True Range: $0.08
HV 20: 70.9%
HV 30: 65.6%
HV 60: 58.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All OPK news →
Earnings History
21 of 24 under expected move
Avg Expected Move
23.23%
Avg Actual Move
6.85%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-18 | After-Close | 13.62% | 10.26% | 0.75x | Within |
| 2021-04-28 | After-Close | 9.62% | 1.20% | 0.12x | Within |
| 2021-07-29 | After-Close | 9.12% | 7.77% | 0.85x | Within |
| 2021-10-28 | After-Close | 9.26% | 3.27% | 0.35x | Within |
| 2022-02-24 | After-Close | 12.07% | 0.93% | 0.08x | Within |
| 2022-05-09 | After-Close | 12.30% | 20.08% | 1.63x | Exceeded |
| 2022-08-04 | After-Close | 14.58% | 5.00% | 0.34x | Within |
| 2022-11-08 | After-Close | 10.27% | 16.22% | 1.58x | Exceeded |
| 2023-02-23 | After-Close | 35.71% | 5.36% | 0.15x | Within |
| 2023-05-03 | After-Close | 32.68% | 10.46% | 0.32x | Within |
| 2023-08-03 | After-Close | 15.14% | 7.57% | 0.50x | Within |
| 2023-11-06 | After-Close | 88.06% | 0.00% | 0.00x | Within |
| 2024-02-27 | After-Close | 22.86% | 6.14% | 0.27x | Within |
| 2024-05-07 | After-Close | 12.31% | 3.85% | 0.31x | Within |
| 2024-08-07 | Pre-Market | 27.99% | 4.48% | 0.16x | Within |
| 2024-11-07 | Pre-Market | 8.50% | 1.36% | 0.16x | Within |
| 2025-02-27 | After-Close | 19.94% | 6.75% | 0.34x | Within |
| 2025-04-30 | After-Close | 16.30% | 2.17% | 0.13x | Within |
| 2025-07-31 | After-Close | 19.53% | 7.03% | 0.36x | Within |
| 2025-10-29 | After-Close | 15.73% | 2.10% | 0.13x | Within |
| 2026-02-26 | After-Close | 29.17% | 0.00% | 0.00x | Within |
| 2026-04-28 | After-Close | 64.05% | 8.26% | 0.13x | Within |
| 2026-07-27 | After-Close | 26.21% | 33.06% | 1.26x | Exceeded |
| 2026-11-04 | After-Close | 32.49% | 1.13% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
OPK Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.53
7-DTE Move: $0.43
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 303
Put Volume: 230
P/C Volume: 0.759
NEUTRAL
Call OI: 36,917
Put OI: 1,474
P/C OI: 0.04
Total OI: 38,391
ATM Options Pricing
ATM Call: $0.03
ATM Put: $0.50
Call %: 1.4%
Put %: 28.2%
Chain Summary
Chain Volume: 533
Chain OI: 38,391
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 94th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
94%
vs own history
GEX tilt
+0.97
OI-weighted, today
Vanna tilt
+0.98
δ-sensitivity to IV
Charm tilt
-0.98
δ-decay vs time
Vanna tilt +0.98: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.98: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.53Nov 9
Beta Analysis
Risk Metrics
Beta: 0.8612
Alpha: 32.43%
Correlation: 0.2073
R-Squared: 4.3%
Stock Volatility: 57.2%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own OPK
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $2.1M | #2850 of 6285 | -31.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $218K | #1770 of 1945 | +55.6% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $108K | #3604 of 3716 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1K | #4582 of 4729 | -62.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
OPK Institutional Ownership (13F)
Filings for 2026-06-30 · 88 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 756,412,676 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
7 filers$715.56K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $278.05K | 38.86% | 2026-09-30 |
| 2 | Citadel Advisors LLC Custodian | $156.15K | 21.82% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $89.52K | 12.51% | 2026-09-30 |
| 4 | Susquehanna International Group, LLP Custodian | $89.25K | 12.47% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $53.85K | 7.53% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $38.25K | 5.35% | 2026-06-30 |
| 7 | Raiffeisen Bank International AG | $10.50K | 1.47% | 2026-09-30 |
5 filers$169.05K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $91.05K | 53.86% | 2026-06-30 |
| 2 | IMC-Chicago, LLC Custodian | $38.96K | 23.05% | 2026-09-30 |
| 3 | Simplex Trading, LLC Custodian | $19.48K | 11.52% | 2026-09-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $18.75K | 11.09% | 2026-06-30 |
| 5 | WOLVERINE ASSET MANAGEMENT LLC | $805 | 0.48% | 2026-09-30 |
OPK Insider Trading (Form 4)
Latest: 2026-11-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-05 | John A Paganelli | Director | Sell (S) | −13,601 | $1.81 | -$24.6K | EDGAR |
| 2026-07-28 | Steven D Rubin | Executive VP-Administration | Tax (F) | −53,266 | $1.22 | -$65.0K | EDGAR |
| 2026-07-28 | Adam Logal | Sr. Vice President, CFO | Tax (F) | −53,266 | $1.22 | -$65.0K | EDGAR |
| 2026-06-22 | John A Paganelli | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-22 | Roger Md Medel | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-22 | Alice Lin-Tsing Yu | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-22 | Subbarao V Uppaluri | Director | Grant (A) | +80,000 opt | — | EDGAR | |
| 2026-06-22 | Prem A Lachman | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-06-22 | Richard C Pfenniger Jr | Director | Grant (A) | +60,000 opt | — | EDGAR | |
| 2026-03-20 | Subbarao V Uppaluri | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2026-03-20 | John A Paganelli | Director | Buy (P) | +10,000 | $1.14 | $11.3K | EDGAR |
| 2025-11-21 | Frost Gamma Investments Trust | 10%+ Owner | Buy (P) | +580,000 | $1.33 | $768.8K | EDGAR |
| 2025-11-20 | Frost Gamma Investments Trust | 10%+ Owner | Buy (P) | +580,000 | $1.33 | $771.3K | EDGAR |
| 2025-11-19 | Frost Gamma Investments Trust | 10%+ Owner | Buy (P) | +580,000 | $1.31 | $759.1K | EDGAR |
| 2025-11-18 | Phillip Md Et Al Frost | CEO & Chairman | Mixed Buy +533,300 · Grant +46,700 |
+580,000 | $1.27 | $737.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
OPK Insider Holdings
12 insiders · @ $1.77
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frost Gamma Investments Trust | 10%+ Owner | 219,801,664 | $390.15M | $172.85M | 699 | 2025-11-21 |
| 2 | Phillip Md Et Al Frost | CEO & Chairman | 33,696,128 | $59.81M | $202.86M | 722 | 2025-11-18 |
| 3 | Jane Ph D Hsiao | Vice Chairman & CTO | 33,627,284 | $59.69M | $25.71M | 61 | 2025-05-29 |
| 4 | Steven D Rubin | Executive VP-Administration | 26,663,028 | $47.33M | $436.2K | 40 | 2026-07-28 |
| 5 | Elias A. Zerhouni | Vice Chairman and President | 20,367,114 | $36.15M | $764.5K | 6 | 2025-05-29 |
| 6 | Subbarao V Uppaluri | Sr Vice President - CFO | 3,984,869 | $7.07M | $445.4K | 14 | 2026-06-22 |
| 7 | Gary J. Nabel | Chief Innovation Officer | 1,052,021 | $1.87M | $1.86M | 9 | 2025-05-29 |
| 8 | Adam Logal | Sr. Vice President, CFO | 563,396 | $1.00M | -$2.17M | 28 | 2026-07-28 |
| 9 | John A Paganelli | Director | 389,914 | $692.1K | $419.4K | 50 | 2026-11-05 |
| 10 | Richard C Pfenniger Jr | Director | 325,000 | $576.9K | $256.2K | 28 | 2026-06-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
OPK Board & Officers
As of SEC filings through Nov 5, 2026Directors 11
- Jane Ph D Hsiao · since Feb 9, 2007
- Steven D Rubin · since Feb 9, 2007
- Phillip Md Et Al Frost · listed since Mar 2007
- Richard C Pfenniger Jr · since Jan 24, 2008
- John A Paganelli · listed since Jul 2008
- Alice Lin-Tsing Yu · since Apr 21, 2009
- Roger Md Medel · since Dec 18, 2020
- Prem A Lachman · since Mar 1, 2021
- Elias A. Zerhouni · since May 9, 2022
- Gary J. Nabel · since May 9, 2022
- Subbarao V Uppaluri · listed since Mar 2026
Officers 6
- Phillip Md Et Al Frost · CEO & Chairman · listed since May 2007
- Adam Logal · Sr. Vice President, CFO · listed since Apr 2014
- Elias A. Zerhouni · Vice Chairman and President · since May 9, 2022
- Gary J. Nabel · Chief Innovation Officer · since May 9, 2022
- Steven D Rubin · Executive VP-Administration · listed since Dec 2007
- Jane Ph D Hsiao · Vice Chairman & CTO · listed since Apr 2008
10% owners 2
- Frost Gamma Investments Trust (entity) · since Feb 9, 2007
- Phillip Md Et Al Frost · since Feb 9, 2007
Changes in the last 10 years (21)
| Mar 20, 2026 | Subbarao V Uppaluri no longer listed as Sr Vice President - CFO in SEC filings |
| Mar 20, 2026 | Subbarao V Uppaluri first listed as a director in an SEC filing |
| Mar 18, 2026 | The company announced the departure of Richard M Krasno from the board in an SEC filing |
| Feb 9, 2024 | The company announced the departure of Alexis Borisy from the board in an SEC filing |
| Aug 16, 2022 | The company announced the departure of Jon R Cohen from the board in an SEC filing |
| Aug 16, 2022 | The company announced the departure of Jon R Cohen as SVP OPKO; Exec Chairman BRLI in an SEC filing |
| May 9, 2022 | Gary J. Nabel became a director |
| May 9, 2022 | Gary J. Nabel became Chief Innovation Officer |
| May 9, 2022 | Elias A. Zerhouni became a director |
| May 9, 2022 | Elias A. Zerhouni became Vice Chairman and President |
| May 9, 2022 | Alexis Borisy became a director |
| Jan 21, 2022 | The company announced the departure of Robert Scott Fishel from the board in an SEC filing |
| Mar 1, 2021 | Prem A Lachman became a director |
| Dec 18, 2020 | Roger Md Medel became a director |
| Jul 23, 2020 | Jon R Cohen became a director |
| Jul 23, 2020 | Jon R Cohen became SVP OPKO; Exec Chairman BRLI |
| Jul 22, 2020 | Rulfo Fernando Hernandez became CAO, Treasurer |
| Jan 6, 2020 | Anthony J Japour became a director |
| Apr 3, 2018 | Robert Scott Fishel became a director |
| Sep 15, 2017 | Frost Nevada Investments Trust first on file as a 10% owner |
| Feb 9, 2017 | Richard M Krasno became a director |
Not reported recently (6)
- Richard A Lerner · Last reported as a director in an SEC filing dated Jun 25, 2021
- Rulfo Fernando Hernandez · Last reported as CAO, Treasurer in an SEC filing dated Jul 24, 2020
- Anthony J Japour · Last reported as a director in an SEC filing dated Mar 13, 2020
- Frost Nevada Investments Trust · Last reported as a 10% owner in an SEC filing dated Jul 17, 2019
- Robert A Baron · Last reported as a director in an SEC filing dated Jan 23, 2017
- Thomas E Beier · Last reported as a director in an SEC filing dated Jan 17, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
38 ETFs hold OPK
25 shown · $87.81M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.02% | $17.7M | $76.6B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $15.7M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.01% | $10.8M | — | 2026-09-30 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $7.7M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.05% | $6.6M | $13.9B | 2026-11-06 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.04% | $4.8M | $11.1B | 2026-11-06 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.7M | — | 2026-09-30 |
| 8 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.01% | $3.5M | — | 2026-09-30 |
| 9 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.01% | $3.0M | — | 2026-09-30 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $3.0M | — | 2026-08-31 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.9M | — | 2026-09-30 |
| 12 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 0.09% | $1.4M | $1.5B | 2026-11-06 |
| 13 | XHS State Street® SPDR® S&P® Health Care Services ETF | SPDR (State Street) | 0.56% | $1.4M | $242.8M | 2026-11-05 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.3M | $93.2B | 2026-11-06 |
| 15 | ISRA VanEck Israel ETF | VanEck | 0.55% | $765,634 | $143.6M | 2026-11-05 |
| 16 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $711,461 | $10.0B | 2026-11-05 |
| 17 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.07% | $708,984 | $1.0B | 2026-11-05 |
| 18 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.04% | $591,406 | — | 2026-09-30 |
| 19 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $531,699 | — | 2026-11-05 |
| 20 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $522,428 | — | 2026-07-31 |
| 21 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $439,931 | — | 2026-08-31 |
| 22 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.01% | $344,332 | $4.0B | 2026-11-05 |
| 23 | RSSL Global X Russell 2000 ETF | Global X | 0.02% | $328,648 | — | 2026-11-06 |
| 24 | SMMV iShares MSCI USA Small-Cap Min Vol Factor ETF | iShares (BlackRock) | 0.08% | $220,559 | $277.0M | 2026-11-06 |
| 25 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $182,617 | $19.7B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.19
TTM Revenue
$501.64M
TTM Net Income
$-148.06M
TTM Op. Cash Flow
$-125.05M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $65.41M | $-53.53M | $-0.07 | $-36.31M |
| Q2 '26 | 2026-06-30 | $163.58M | $-8.42M | $-0.01 | $-43.50M |
| Q1 '26 | 2026-03-31 | $124.20M | $-54.85M | $-0.07 | $-19.31M |
| Q4 '25 | 2025-12-31 | $148.45M | $-31.26M | $-0.04 | $-25.92M |
| Q3 '25 | 2025-09-30 | $56.42M | $21.63M | $0.03 | $-34.65M |
| Q2 '25 | 2025-06-30 | $156.81M | $-148.44M | $-0.19 | $-83.42M |
| Q1 '25 | 2025-03-31 | $149.95M | $-67.61M | $-0.10 | $-34.55M |
| Q4 '24 | 2024-12-31 | $183.64M | $14.03M | $0.02 | $-44.41M |
| Q3 '24 | 2024-09-30 | $173.63M | $24.89M | $0.03 | $-77.08M |
| Q2 '24 | 2024-06-30 | $182.19M | $-10.30M | $-0.01 | $-26.43M |
| Q1 '24 | 2024-03-31 | $173.69M | $-81.84M | $-0.12 | $-35.57M |
| Q4 '23 | 2023-12-31 | $181.90M | $-66.48M | $-0.09 | $-38.29M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.14
P/S
2.29
EV/EBITDA
—
EV/Sales
2.35
ROE
-6.2%
ROA
-4.0%
Div Yield
0.00%
FCF Yield
-9.16%
Debt/Equity
0.28
Current Ratio
—
Market Cap
$1.35B
as of 2026-11-09
OPK vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $353.2B | 30.0 | +9.7% | +18.3% | 44 |
| HCA HCA Healthcare, Inc. | $103.4B | 16.7 | +5.8% | +7.4% | 21 |
| ELV Elevance Health, Inc. | $92.0B | 17.9 | +3.6% | +18.5% | 31 |
| CI The Cigna Group | $77.6B | 13.0 | +6.8% | +5.7% | 32 |
| TEVA Teva Pharmaceutical Industries Limited | $49.7B | 99.8 | +2.7% | +38.7% | 25 |
| CNC Centene Corporation | $34.5B | 23.7 | +9.7% | +65.4% | 38 |
| LH Labcorp Holdings Inc. | $29.8B | 30.8 | +6.4% | +48.0% | 41 |
| SGRY Surgery Partners, Inc. Common Stock | $3.0B | — | +5.4% | +71.8% | 31 |
| OPK Opko Health Inc. | $1.3B | — | −8.3% | +39.8% | 17 |
| Peer median | $63.6B | 23.7 | +6.1% | +28.6% | 31 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
34.01M
SI % of Float
9.32%
Days to Cover
5.26
Short Vol Ratio
69.2%
Free Float
365.03M
Float %
48.9%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14